( September 17, 2025, 22:31 GMT | Official Statement) -- MLex Summary: CareFirst opposed Johnson & Johnson and Janssen Biotech’s motion for judgment in a US antitrust case over Stelara, arguing a reasonable jury could find in favor of the plaintiffs on both the Walker Process and the Momenta patent acquisition aspects of the monopolistic scheme. “As to the former, there is an abundance of disputed facts, a situation not atypical for fraud cases. As to the latter, J&J raises no legally material challenge, so the plaintiffs are entitled to partial summary judgment in their favor,” CareFirst said. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.